Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial

Susanne A. Gatz, Pablo Berlanga, Gwénaël Le Teuff, Ivan Valiev, Amaury Leruste, Nicolas André, Dominique Bluteau, Nadege Corradini, Jonathan Rubino, Fabienne Thomas, Souad Nebchi, Eleni Karamouza, Jeanne Petit, Estelle Thebaud, Alba Rubio-San-Simón, Natasha K.A. van Eijkelenburg, Lynley V. Marshall, Sandra Raimbault, Adela Canete, Stephane Ducassou, Guy Makin, Michela Casanova, Emilie De Carli, Arnaud Petit, Melis Cardon, Ludovic Lacroix, Gaelle Pierron, Gudrun Schleiermacher, Michael J.F. Hubank, Aroa Soriano Fernandez, Karin P.S. Langenberg, David Castel, Tiphaine Adam-de Beaumais, Xavier Paoletti, Pradeep B. Lukka, Richard Baldry, Peter G.S. Mortimer, Sergey I. Nikolaev, Birgit Geoerger

Open source

DOI: 10.1158/1078-0432.ccr-25-3767
Published: 2026-01-27
Container: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-3767,
  title = {Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial},
  author = {Susanne A. Gatz and Pablo Berlanga and Gwénaël Le Teuff and Ivan Valiev and Amaury Leruste and Nicolas André and Dominique Bluteau and Nadege Corradini and Jonathan Rubino and Fabienne Thomas and Souad Nebchi and Eleni Karamouza and Jeanne Petit and Estelle Thebaud and Alba Rubio-San-Simón and Natasha K.A. van Eijkelenburg and Lynley V. Marshall and Sandra Raimbault and Adela Canete and Stephane Ducassou and Guy Makin and Michela Casanova and Emilie De Carli and Arnaud Petit and Melis Cardon and Ludovic Lacroix and Gaelle Pierron and Gudrun Schleiermacher and Michael J.F. Hubank and Aroa Soriano Fernandez and Karin P.S. Langenberg and David Castel and Tiphaine Adam-de Beaumais and Xavier Paoletti and Pradeep B. Lukka and Richard Baldry and Peter G.S. Mortimer and Sergey I. Nikolaev and Birgit Geoerger},
  year = {2026},
  journal = {Clinical Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-3767},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-3767}
}

RIS

TY  - JOUR
TI  - Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
AU  - Susanne A. Gatz
AU  - Pablo Berlanga
AU  - Gwénaël Le Teuff
AU  - Ivan Valiev
AU  - Amaury Leruste
AU  - Nicolas André
AU  - Dominique Bluteau
AU  - Nadege Corradini
AU  - Jonathan Rubino
AU  - Fabienne Thomas
AU  - Souad Nebchi
AU  - Eleni Karamouza
AU  - Jeanne Petit
AU  - Estelle Thebaud
AU  - Alba Rubio-San-Simón
AU  - Natasha K.A. van Eijkelenburg
AU  - Lynley V. Marshall
AU  - Sandra Raimbault
AU  - Adela Canete
AU  - Stephane Ducassou
AU  - Guy Makin
AU  - Michela Casanova
AU  - Emilie De Carli
AU  - Arnaud Petit
AU  - Melis Cardon
AU  - Ludovic Lacroix
AU  - Gaelle Pierron
AU  - Gudrun Schleiermacher
AU  - Michael J.F. Hubank
AU  - Aroa Soriano Fernandez
AU  - Karin P.S. Langenberg
AU  - David Castel
AU  - Tiphaine Adam-de Beaumais
AU  - Xavier Paoletti
AU  - Pradeep B. Lukka
AU  - Richard Baldry
AU  - Peter G.S. Mortimer
AU  - Sergey I. Nikolaev
AU  - Birgit Geoerger
PY  - 2026
JO  - Clinical Cancer Research
DO  - 10.1158/1078-0432.ccr-25-3767
UR  - https://doi.org/10.1158/1078-0432.ccr-25-3767
ER  -

APA

Gatz, S. A., Berlanga, P., Teuff, G. L., Valiev, I., Leruste, A., André, N., Bluteau, D., Corradini, N., Rubino, J., Thomas, F., Nebchi, S., Karamouza, E., Petit, J., Thebaud, E., Rubio-San-Simón, A., Eijkelenburg, N. K. V., Marshall, L. V., Raimbault, S., Canete, A., Ducassou, S., Makin, G., Casanova, M., Carli, E. D., Petit, A., Cardon, M., Lacroix, L., Pierron, G., Schleiermacher, G., Hubank, M. J., Fernandez, A. S., Langenberg, K. P., Castel, D., Beaumais, T. A., Paoletti, X., Lukka, P. B., Baldry, R., Mortimer, P. G., Nikolaev, S. I., & Geoerger, B. (2026). Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-3767

Source records

crossref · retrieved 2026-09-27T01:36:42.341Z